Thomas R. Kosten

1 month ago | onlinelibrary.wiley.com | Thomas R. Kosten |Coreen Domingo

INTRODUCTION Proceedings of the 35th Annual Meeting & Scientific Symposium Thomas R. Kosten MD,  Thomas R. Kosten MD Editor-in-Chief Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USASearch for more papers by this authorCoreen B. Domingo DrPH, MSW,  Coreen B. Domingo DrPH, MSW Deputy Editor Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USASearch for more papers by this author Thomas R.

Dec 10, 2024 | psychiatrictimes.com | Heidi Anne Duerr |Thomas R. Kosten

CommentaryArticleDecember 10, 2024Author(s):,Thomas R. Kosten, MD, shares thoughts on the latest schizophrenia genetic model research presented at the meeting. Sharing his thoughts at the 63rd Annual Meeting of the American College of Neuropsychopharmacology, Thomas R. Kosten, MD, member of the Psychiatric Times editorial board, discussed research on the genetic underpinnings of schizophrenia.

Dec 9, 2024 | psychiatrictimes.com | Heidi Anne Duerr |Thomas R. Kosten

Promising advances are being discussed at the 63rd Annual Meeting of the American College of Neurpsychopharmacology in Phoenix, Arizona. Kosten, a member of the Psychiatric Times editorial board, shared his thoughts on the meeting itself as well as the presentations for promising new targets. Although still early in the meeting, he has already attended several presentations, including the Promising Targets Oral Session.

May 6, 2024 | ajp.psychiatryonline.org | Thomas R. Kosten

Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Register for access Purchase Save for later Item saved, go to cart Not a subscriber? Subscribe Now / Learn MorePsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources.

Mar 14, 2024 | nature.com | Tim B. Bigdeli |Peter Barr |Jacquelyn L. Meyers |Bryan R. Gorman |David A Nielsen |Hongyu Zhao | +7 more

AbstractPersons diagnosed with schizophrenia (SCZ) or bipolar I disorder (BPI) are at high risk for self-injurious behavior, suicidal ideation, and suicidal behaviors (SB). Characterizing associations between diagnosed health problems, prior pharmacological treatments, and polygenic scores (PGS) has potential to inform risk stratification.